サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1746516

日本の潰瘍性大腸炎市場レポート：タイプ別、疾患タイプ別、分子タイプ別、薬剤タイプ別、投与経路別、流通チャネル別、地域別、2025年～2033年

Japan Ulcerative Colitis Market Report by Type, Disease Type, Molecule Type, Drug Type, Route of Administration, Distribution Channel, and Region 2025-2033

出版日
発行
IMARC
ページ情報
英文 120 Pages
納期
5～7営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.08円
日本の潰瘍性大腸炎市場レポート：タイプ別、疾患タイプ別、分子タイプ別、薬剤タイプ別、投与経路別、流通チャネル別、地域別、2025年～2033年
出版日: 2025年06月02日
発行: IMARC
ページ情報: 英文 120 Pages
納期: 5～7営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

日本の潰瘍性大腸炎市場規模は2024年に3億4,600万米ドルに達しました。今後、IMARC Groupでは、2033年には5億6,250万米ドルに達し、2025年から2033年にかけて5.13%の成長率（CAGR）を示すと予測しています。日本の潰瘍性大腸炎の普及率の上昇、ヘルスケアインフラと高度医療技術の向上、研究開発（R&D）の取り組みの拡大、急速な技術進歩、医療機関や患者支援団体による社会的認知度向上への取り組みなどが、市場を牽引する主な要因となっています。

本レポートで扱う主な質問

  • 日本の潰瘍性大腸炎市場はこれまでどのように推移し、今後どのように推移するのか？
  • COVID-19が日本の潰瘍性大腸炎市場に与えた影響は？
  • 日本の潰瘍性大腸炎市場のタイプ別区分は？
  • 日本の潰瘍性大腸炎市場の疾患タイプ別区分は？
  • 日本の潰瘍性大腸炎市場の分子タイプ別区分は？
  • 日本の潰瘍性大腸炎市場の薬剤タイプ別区分は？
  • 日本の潰瘍性大腸炎市場の投与経路別区分は？
  • 日本の潰瘍性大腸炎市場の流通チャネル別の区分は？
  • 日本の潰瘍性大腸炎市場のバリューチェーンにおける様々な段階とは？
  • 日本の潰瘍性大腸炎市場の主要な促進要因と課題は何か？
  • 日本の潰瘍性大腸炎市場の構造と主要企業は？
  • 日本の潰瘍性大腸炎市場における競合の程度は？

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査の目的
  • ステークホルダー
  • データソース
  • 市場推定
  • 調査手法

第3章 エグゼクティブサマリー

第4章 日本の潰瘍性大腸炎市場-イントロダクション

  • 概要
  • 市場力学
  • 業界動向
  • 競合情報

第5章 日本の潰瘍性大腸炎市場情勢

  • 過去および現在の市場動向（2019～2024年）
  • 市場予測（2025～2033年）

第6章 日本の潰瘍性大腸炎市場- タイプ別の内訳

  • 軽度のUC
  • 中等度のUC
  • 重度のUC

第7章 日本の潰瘍性大腸炎市場- 疾患タイプ別の内訳

  • 潰瘍性直腸炎
  • 直腸S状結腸炎
  • 左側大腸炎
  • 全大腸炎または汎発性大腸炎
  • 劇症大腸炎

第8章 日本の潰瘍性大腸炎市場- 分子タイプ別の内訳

  • 小分子
  • 生物学的製剤

第9章 日本の潰瘍性大腸炎市場- 薬剤タイプ別の内訳

  • 抗炎症薬
  • 抗TNF生物学的製剤
  • 免疫抑制剤
  • カルシニューリン阻害剤
  • その他

第10章 日本の潰瘍性大腸炎市場- 投与経路別の内訳

  • 経口
  • 注射剤

第11章 日本の潰瘍性大腸炎市場- 流通チャネル別内訳

  • 病院薬局
  • 小売薬局
  • ドラッグストア
  • その他

第12章 日本の潰瘍性大腸炎市場-競合情勢

  • 概要
  • 市場構造
  • 市場企業のポジショニング
  • 主要成功戦略
  • 競合ダッシュボード
  • 企業評価象限

第13章 主要企業のプロファイル

第14章 日本の潰瘍性大腸炎市場- 業界分析

  • 促進要因・抑制要因・機会
  • ポーターのファイブフォース分析
  • バリューチェーン分析

第15章 付録

目次
Product Code: SR112025A19356

The Japan ulcerative colitis market size reached USD 346.0 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 562.5 Million by 2033, exhibiting a growth rate (CAGR) of 5.13% during 2025-2033. The increasing prevalence of ulcerative colitis in Japan, rising healthcare infrastructure and advanced medical technologies, growing research and development (R&D) initiatives, rapid technological advancements, and heightened public awareness initiatives by healthcare organizations and patient advocacy groups represent some of the key factors driving the market.

Ulcerative colitis refers to an inflammatory bowel disease that adversely affects the lining of the large intestine and rectum. It exhibits various symptoms, such as persistent diarrhea, rectal bleeding, abdominal pain, fatigue, and weight loss. Ulcerative colitis is suspected to be caused by a combination of environmental factors, genetic predisposition, and an overactive immune response. It is diagnosed through multiple tests, such as stool samples, blood tests, colonoscopy, and imaging studies. Ulcerative colitis is treated using anti-inflammatory medications, immunosuppressants, and, in more severe cases, surgical intervention. The treatments offer numerous benefits, including symptom relief, decreased frequency of flare-ups, and reduced risk of complications, such as colon cancer. They also improve the overall quality of life for patients by enabling better nutrient absorption and digestive function. Moreover, the therapies, backed by rigorous scientific research, provide patients with substantial advantages, such as long-lasting remission periods and a decreased need for hospitalization.

Japan Ulcerative Colitis Market Trends:

The increasing prevalence of ulcerative colitis in Japan is one of the major factors contributing to the market growth. Moreover, the presence of a high-quality healthcare infrastructure and advanced medical technologies, allowing for precise diagnosis and effective management of the disease, is creating a positive outlook for the market growth. Additionally, the growing focus of the pharmaceutical industry on research and development (R&D) of new drugs and therapies, aided by government support in the form of grants and policies, is supporting the market growth. Along with this, rapid technological advancements, such as the integration of artificial intelligence (AI) in diagnostic procedures and data analytics, enabling healthcare providers to develop personalized treatment plans, are enhancing the market growth. In addition to this, the increasing adoption of telemedicine platforms, allowing for more frequent and convenient patient-doctor interactions, is bolstering the market growth. Besides this, the rising public awareness initiatives by healthcare organizations and patient advocacy groups, raising the profile of the disease and leading to earlier diagnosis, are anticipated to drive the market growth. Apart from this, the growing geriatric population in Japan, resulting in heightened incidences of ulcerative colitis, is also stimulating the market growth. Furthermore, the rising partnerships between pharmaceutical companies and academic institutions, fostering innovation in drug development and research, are positively influencing the market growth. In line with this, the introduction of new biologic drugs, offering effective results, fewer side effects, longer remission periods, and reduced hospital visits, are providing a thrust to the market growth. Moreover, the increasing focus by companies on patient education and compliance programs to improve long-term treatment outcomes is offering lucrative growth opportunities for the market across the country.

Japan Ulcerative Colitis Market Segmentation:

Type Insights:

  • Mild UC
  • Moderate UC
  • Severe UC

Disease Type Insights:

  • Ulcerative Proctitis
  • Proctosigmoiditis
  • Left-sided Colitis
  • Pancolitis or Universal Colitis
  • Fulminant Colitis

Molecule Type Insights:

  • Small Molecules
  • Biologics

Drug Type Insights:

  • Anti-Inflammatory Drugs
  • Anti-TNF Biologics
  • Immunosuppressant
  • Calcineurin Inhibitors
  • Others

Route of Administration Insights:

  • Oral
  • Injectable

Distribution Channel Insights:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Drug Store
  • Others

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.

Key Questions Answered in This Report:

  • How has the Japan ulcerative colitis market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the Japan ulcerative colitis market?
  • What is the breakup of the Japan ulcerative colitis market on the basis of type?
  • What is the breakup of the Japan ulcerative colitis market on the basis of disease type?
  • What is the breakup of the Japan ulcerative colitis market on the basis of molecule type?
  • What is the breakup of the Japan ulcerative colitis market on the basis of drug type?
  • What is the breakup of the Japan ulcerative colitis market on the basis of route of administration?
  • What is the breakup of the Japan ulcerative colitis market on the basis of distribution channel?
  • What are the various stages in the value chain of the Japan ulcerative colitis market?
  • What are the key driving factors and challenges in the Japan ulcerative colitis?
  • What is the structure of the Japan ulcerative colitis market and who are the key players?
  • What is the degree of competition in the Japan ulcerative colitis market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Japan Ulcerative Colitis Market - Introduction

  • 4.1 Overview
  • 4.2 Market Dynamics
  • 4.3 Industry Trends
  • 4.4 Competitive Intelligence

5 Japan Ulcerative Colitis Market Landscape

  • 5.1 Historical and Current Market Trends (2019-2024)
  • 5.2 Market Forecast (2025-2033)

6 Japan Ulcerative Colitis Market - Breakup by Type

  • 6.1 Mild UC
    • 6.1.1 Overview
    • 6.1.2 Historical and Current Market Trends (2019-2024)
    • 6.1.3 Market Forecast (2025-2033)
  • 6.2 Moderate UC
    • 6.2.1 Overview
    • 6.2.2 Historical and Current Market Trends (2019-2024)
    • 6.2.3 Market Forecast (2025-2033)
  • 6.3 Severe UC
    • 6.3.1 Overview
    • 6.3.2 Historical and Current Market Trends (2019-2024)
    • 6.3.3 Market Forecast (2025-2033)

7 Japan Ulcerative Colitis Market - Breakup by Disease Type

  • 7.1 Ulcerative Proctitis
    • 7.1.1 Overview
    • 7.1.2 Historical and Current Market Trends (2019-2024)
    • 7.1.3 Market Forecast (2025-2033)
  • 7.2 Proctosigmoiditis
    • 7.2.1 Overview
    • 7.2.2 Historical and Current Market Trends (2019-2024)
    • 7.2.3 Market Forecast (2025-2033)
  • 7.3 Left-sided Colitis
    • 7.3.1 Overview
    • 7.3.2 Historical and Current Market Trends (2019-2024)
    • 7.3.3 Market Forecast (2025-2033)
  • 7.4 Pancolitis or Universal Colitis
    • 7.4.1 Overview
    • 7.4.2 Historical and Current Market Trends (2019-2024)
    • 7.4.3 Market Forecast (2025-2033)
  • 7.5 Fulminant Colitis
    • 7.5.1 Overview
    • 7.5.2 Historical and Current Market Trends (2019-2024)
    • 7.5.3 Market Forecast (2025-2033)

8 Japan Ulcerative Colitis Market - Breakup by Molecule Type

  • 8.1 Small Molecules
    • 8.1.1 Overview
    • 8.1.2 Historical and Current Market Trends (2019-2024)
    • 8.1.3 Market Forecast (2025-2033)
  • 8.2 Biologics
    • 8.2.1 Overview
    • 8.2.2 Historical and Current Market Trends (2019-2024)
    • 8.2.3 Market Forecast (2025-2033)

9 Japan Ulcerative Colitis Market - Breakup by Drug Type

  • 9.1 Anti-Inflammatory Drugs
    • 9.1.1 Overview
    • 9.1.2 Historical and Current Market Trends (2019-2024)
    • 9.1.3 Market Forecast (2025-2033)
  • 9.2 Anti-TNF Biologics
    • 9.2.1 Overview
    • 9.2.2 Historical and Current Market Trends (2019-2024)
    • 9.2.3 Market Forecast (2025-2033)
  • 9.3 Immunosuppressant
    • 9.3.1 Overview
    • 9.3.2 Historical and Current Market Trends (2019-2024)
    • 9.3.3 Market Forecast (2025-2033)
  • 9.4 Calcineurin Inhibitors
    • 9.4.1 Overview
    • 9.4.2 Historical and Current Market Trends (2019-2024)
    • 9.4.3 Market Forecast (2025-2033)
  • 9.5 Others
    • 9.5.1 Historical and Current Market Trends (2019-2024)
    • 9.5.2 Market Forecast (2025-2033)

10 Japan Ulcerative Colitis Market - Breakup by Route of Administration

  • 10.1 Oral
    • 10.1.1 Overview
    • 10.1.2 Historical and Current Market Trends (2019-2024)
    • 10.1.3 Market Forecast (2025-2033)
  • 10.2 Injectable
    • 10.2.1 Overview
    • 10.2.2 Historical and Current Market Trends (2019-2024)
    • 10.2.3 Market Forecast (2025-2033)

11 Japan Ulcerative Colitis Market - Breakup by Distribution Channel

  • 11.1 Hospital Pharmacies
    • 11.1.1 Overview
    • 11.1.2 Historical and Current Market Trends (2019-2024)
    • 11.1.3 Market Forecast (2025-2033)
  • 11.2 Retail Pharmacies
    • 11.2.1 Overview
    • 11.2.2 Historical and Current Market Trends (2019-2024)
    • 11.2.3 Market Forecast (2025-2033)
  • 11.3 Drug Store
    • 11.3.1 Overview
    • 11.3.2 Historical and Current Market Trends (2019-2024)
    • 11.3.3 Market Forecast (2025-2033)
  • 11.4 Others
    • 11.4.1 Historical and Current Market Trends (2019-2024)
    • 11.4.2 Market Forecast (2025-2033)

12 Japan Ulcerative Colitis Market - Competitive Landscape

  • 12.1 Overview
  • 12.2 Market Structure
  • 12.3 Market Player Positioning
  • 12.4 Top Winning Strategies
  • 12.5 Competitive Dashboard
  • 12.6 Company Evaluation Quadrant

13 Profiles of Key Players

  • 13.1 Company A
    • 13.1.1 Business Overview
    • 13.1.2 Services Offered
    • 13.1.3 Business Strategies
    • 13.1.4 SWOT Analysis
    • 13.1.5 Major News and Events
  • 13.2 Company B
    • 13.2.1 Business Overview
    • 13.2.2 Services Offered
    • 13.2.3 Business Strategies
    • 13.2.4 SWOT Analysis
    • 13.2.5 Major News and Events
  • 13.3 Company C
    • 13.3.1 Business Overview
    • 13.3.2 Services Offered
    • 13.3.3 Business Strategies
    • 13.3.4 SWOT Analysis
    • 13.3.5 Major News and Events
  • 13.4 Company D
    • 13.4.1 Business Overview
    • 13.4.2 Services Offered
    • 13.4.3 Business Strategies
    • 13.4.4 SWOT Analysis
    • 13.4.5 Major News and Events
  • 13.5 Company E
    • 13.5.1 Business Overview
    • 13.5.2 Services Offered
    • 13.5.3 Business Strategies
    • 13.5.4 SWOT Analysis
    • 13.5.5 Major News and Events

14 Japan Ulcerative Colitis Market - Industry Analysis

  • 14.1 Drivers, Restraints, and Opportunities
    • 14.1.1 Overview
    • 14.1.2 Drivers
    • 14.1.3 Restraints
    • 14.1.4 Opportunities
  • 14.2 Porters Five Forces Analysis
    • 14.2.1 Overview
    • 14.2.2 Bargaining Power of Buyers
    • 14.2.3 Bargaining Power of Suppliers
    • 14.2.4 Degree of Competition
    • 14.2.5 Threat of New Entrants
    • 14.2.6 Threat of Substitutes
  • 14.3 Value Chain Analysis

15 Appendix